Home

Quest Diagnostics (DGX)

164.89
+0.72 (0.44%)

Quest Diagnostics is a leading global provider of diagnostic information services, specializing in laboratory testing and related services

The company offers a comprehensive range of medical testing, including routine blood work, genetic testing, and specialized diagnostic imaging, aimed at helping healthcare providers make informed decisions about patient care. With a vast network of laboratories and patient service centers, Quest Diagnostics plays a critical role in the healthcare ecosystem by delivering accurate and timely results, contributing to enhanced patient outcomes and supporting public health initiatives. Through their innovative technologies and dedication to quality, the company strives to advance the practice of medicine and improve overall health management.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close164.17
Open163.94
Bid164.70
Ask164.94
Day's Range162.55 - 166.97
52 Week Range123.04 - 167.08
Volume491,988
Market Cap20.15B
PE Ratio (TTM)22.16
EPS (TTM)7.4
Dividend & Yield3.000 (1.82%)
1 Month Average Volume973,728

News & Press Releases

Why Quest Diagnostics Stock Was Blasting Higher Todayfool.com
Via The Motley Fool · January 30, 2025
Quest Diagnostics EPS Tops Predictionsfool.com
Quest Diagnostics saw robust growth in earnings and revenue, surpassing expectations for Q4 2024.
Via The Motley Fool · January 30, 2025
Quest Diagnostics Stock Hits Over 2-Month High On Q4 Beat, Dividend Hike: Retail Cheer Growsstocktwits.com
Quest completed eight acquisitions in 2024, including LifeLabs, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers.
Via Stocktwits · January 30, 2025
Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.chartmill.com
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.
Via Chartmill · January 30, 2025
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · January 30, 2025
Analyst Expectations For Quest Diagnostics's Futurebenzinga.com
Via Benzinga · January 6, 2025
How Is The Market Feeling About Quest Diagnostics?benzinga.com
Via Benzinga · December 31, 2024
The Analyst Landscape: 8 Takes On Quest Diagnosticsbenzinga.com
Via Benzinga · December 10, 2024
Quest Diagnostics Delivers Q4 Earnings Beat: The Detailsbenzinga.com
Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of $2.23 per share, beating estimates of $2.19 per share.
Via Benzinga · January 30, 2025
IBM Posts Upbeat Earnings, Joins Oshkosh, Las Vegas Sands, Nokia, Quest Diagnostics And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · January 30, 2025
Friday's session: top gainers and losers in the S&P500 indexchartmill.com
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · January 24, 2025
Tesla To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Mondaybenzinga.com
Via Benzinga · January 6, 2025
(DGX) - Analyzing Quest Diagnostics's Short Interestbenzinga.com
Via Benzinga · December 2, 2024
How Is The Market Feeling About Quest Diagnostics?benzinga.com
Via Benzinga · November 11, 2024
Earnings Scheduled For January 30, 2025benzinga.com
Via Benzinga · January 30, 2025
This Boeing Analyst Turns Bullish; Here Are Top 5 Upgrades For Mondaybenzinga.com
Via Benzinga · January 6, 2025
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
Quest Diagnostics (NYSEDGX) And Mainz Biomed NASDAQ: MYNZNASDAQMYNZ)
Via News Direct · December 20, 2024
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Servicesbenzinga.com
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
Via Benzinga · December 19, 2024
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval
By Mainz BioMed NV · Via GlobeNewswire · December 19, 2024
Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · December 17, 2024
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesdaybenzinga.com
Via Benzinga · December 17, 2024
Guardant Health Stock Sees RS Rating Jump To 83investors.com
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.
Via Investor's Business Daily · November 20, 2024
Navigating Earnings Season: Weather Any Stormtalkmarkets.com
The consequences of hurricanes like Helene and Milton are—typically—quickly shrugged aside by markets as one-off events. That is mostly correct. But not entirely so. For some companies, the revenue and earnings hits are “unrecoverable.”
Via Talk Markets · November 16, 2024
Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicarebenzinga.com
Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization.
Via Benzinga · November 9, 2024
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impactbenzinga.com
LabCorp Q3 2024 EPS beats expectations at $3.50, with 7.4% revenue growth to $3.28B. Adjusted EPS guidance revised due to weather.
Via Benzinga · October 24, 2024